PIRAMAL PHARMA
|
The Current P/E Ratio of PIRAMAL PHARMA is -70.75.
| Share Price | ₹197.6 | Oct 16,2026 |
| Market Cap | ₹26,306.5 Cr | |
| Earnings-TTM | ₹-371.8 Cr | TTM-Consolidated Results |
| Price/Earnings | -70.75x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of PIRAMAL PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹26,306.5 Cr] as on Oct 16,2026
(/) Earnings [ ₹-371.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -70.75x ]
Thus, for PIRAMAL PHARMA , the investors are currently willing to pay -70.75 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of PIRAMAL PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of PIRAMAL PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of PIRAMAL PHARMA
PE Ratio Performance Analysis for PIRAMAL PHARMA
- PIRAMAL PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 245.53x.
- PIRAMAL PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, PIRAMAL PHARMA 's p/e ratio peaked in Mar2024 at 956.95x.
- PIRAMAL PHARMA 's p/e ratio hit its five-year low in Mar2026 of -55.56x.
How does PIRAMAL PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| PIRAMAL PHARMA | -371.81 | -70.75 | 26,306.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.69 | 422,283.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 83.68 | 244,762.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 80.45 | 173,448.0 |
| CIPLA LTD | 3,364.84 | 31.81 | 107,043.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 32.44 | 102,820.0 |
| MANKIND PHARMA LTD | 2,055.11 | 45.72 | 93,967.8 |
| LUPIN LTD | 5,551.01 | 16.11 | 89,436.8 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.97 | 112,149.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.73 | 95,512.7 |
| LAURUS LABS LTD | 1,090.76 | 101.99 | 111,250.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs PIRAMAL PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -70.75x |
| Max industry PE | 101.99x |
| Median industry PE | 32.44x |
| Average industry PE | 36.99x |
You may also like the below Video Courses